The results of the study indicated that CDPIA significantly alleviated hepatic steatosis in the HFD-induced MASLD mouse model, and long-term injection of CDPIA did not show systemic toxicity in mice, suggesting that CDPIA could effectively control the local secretion of IL-22 and reduce its off-target toxicity (Zai et al., 2019). This evidence concerns the gene IL22 and metabolic dysfunction-associated steatotic liver disease.